The effect of high-dose parenteral vitamin D3 on COVID-19-related inhospital mortality in critical COVID-19 patients during intensive care unit admission: an observational cohort study
Güven,
The effect of high-dose parenteral vitamin D3 on COVID-19-related inhospital mortality in critical COVID-19..,
et al, European Journal of Clinical Nutrition, doi:10.1038/s41430-021-00984-5
Retrospective 175 ICU patients, 113 treated with a single dose of 300,000IU intramuscular cholecalciferol, showing lower mortality with treatment, but not reaching statistical significance. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more successful, especially with this very late stage usage.
This study is excluded in the after exclusion results of meta
analysis:
very late stage, ICU patients.
risk of death, 24.8% lower, RR 0.75, p = 0.32, treatment 43 of 113 (38.1%), control 30 of 62 (48.4%), NNT 9.7, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Güven et al., 23 Jul 2021, retrospective, Turkey, peer-reviewed, 2 authors, dosage 300,000IU single dose.
Abstract: European Journal of Clinical Nutrition
www.nature.com/ejcn
ARTICLE
Nutrition in acute and chronic diseases
The effect of high-dose parenteral vitamin D3 on COVID-19related inhospital mortality in critical COVID-19 patients during
intensive care unit admission: an observational cohort study
Mehmet Güven
1✉
and Hamza Gültekin
2
© The Author(s), under exclusive licence to Springer Nature Limited 2021
BACKGROUND: In many studies, vitamin D has been found to be low in COVID-19 patients. In this study, we aimed to investigate
the relationship between clinical course and inhospital mortality with parenteral administration of high-dose vitamin D3 within the
first 24 h of admission to patients who were hospitalized in the intensive care unit (ICU) because of COVID-19 with vitamin D
deficiency.
METHODS: This study included 175 COVID-19 patients with vitamin D deficiency [25(OH) D <12 ng/mL] who were hospitalized in
the ICU. Vitamin D3 group (n = 113) included patients who received a single dose of 300,000 IU vitamin D3 intramuscularly. Vitamin
D3 was not administered to the control group (n = 62).
RESULTS: Median C-reactive protein level was 10.8 mg/dL in the vitamin D3 group and 10.6 mg/dL in the control group (p = 0.465).
Thirty-nine percent (n = 44) of the patients in the vitamin D3 group were intubated endotracheally, and 50% (n = 31) of the patients
in the control group were intubated endotracheally (p = 0.157). Parenteral vitamin D3 administration was not associated with
inhospital mortality by multivariate logistic regression analysis. According to Kaplan–Meier survival analysis, the median survival
time was 16 d in the vitamin D3 group and 17 d in the control group (log-rank test, p = 0.459).
CONCLUSION: In this study, which was performed for the first time in the literature, it was observed that high-dose parenteral
vitamin D3 administration in critical COVID-19 patients with vitamin D deficiency during admission to the ICU did not reduce the
need for intubation, length of hospital stay, and inhospital mortality.
European Journal of Clinical Nutrition (2021) 75:1383–1388; https://doi.org/10.1038/s41430-021-00984-5
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit